A Study of Loco-Regional Liposomal Bupivacaine Injection - Trial NCT05992896
Access comprehensive clinical trial information for NCT05992896 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mayo Clinic
Timeline & Enrollment
Phase 4
Sep 26, 2023
Feb 01, 2024
Primary Outcome
Postoperative use of narcotics at 12 hours,Postoperative use of narcotics at 24 hours,Postoperative use of narcotics at 48 hours,Postoperative use of narcotics at 72 hours,Postoperative use of narcotics at 30 days
Summary
The purpose of this research is to find out if using liposomal bupivacaine solution
 (bupivacaine liposome) injections during lower extremity revascularization surgery will lower
 the amount of narcotic drugs used during and following the procedure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05992896
Non-Device Trial